ASP-2215 Gilteritinib hemifumarate

Details:

Our Company

Shandong Bolode Bio-Technology Co., Ltd is a professional company which engaged in the R&D  and manufacture of Pharmaceuticals intermediates  and Chemical Raw materials. The company is located in Jinan, the capital of Shandong Province. With the advanced equipment, quality management and many years producing experience, The company has completed quality ass urance system and strong research and innovation ability.

 Purity : 95%+ min

Supply COA , HPLC ,HNMR ,MASS  

Direct  manufacturers with high quality and best price !

Xospata belongs to the second generation of FLT3 inhibitors, which has inhibitory effects on two different mutations in FLT3 transmembrane region internal tandem repeat (ITD) and FLT3 tyrosine kinase domain (TKD). Xospata (Gilteritinib) is a drug that inhibits cell growth by blocking FLT3 and other proteins on cancer cells. This drug can treat adult patients whose leukemia cells have FLT3 gene mutations and whose AML has not been effective in previous treatments or have relapsed.

The drug has been approved for marketing in Japan and the United States in 2018 for the treatment of adult patients with relapsed or refractory FLT3 mutant acute myeloid leukemia. It is the first FDA-approved treatment for relapsed refractory acute myeloid leukemia. FLT3 inhibitor.On April 10, 2020, Astellas announced that it had submitted a new drug listing application (NDA) for Xospata (gilteritinib) giritinib, which was accepted by the National Medical Products Administration (NMPA) for the treatment of FLT3 mutation positive (FLT3mut+) Of adult patients with relapsed or refractory (treatment resistant) acute myeloid leukemia (AML)